139 related articles for article (PubMed ID: 20340055)
21. Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma.
Chow V; Yuen AP; Lam KY; Ho WK; Wei WI
Head Neck; 2001 Apr; 23(4):286-91. PubMed ID: 11400229
[TBL] [Abstract][Full Text] [Related]
22. Serum CXCL12, but not CXCR4, Is Associated with Head and Neck Squamous Cell Carcinomas.
Lavaee F; Zare S; Mojtahedi Z; Malekzadeh M; Khademi B; Ghaderi A
Asian Pac J Cancer Prev; 2018 Apr; 19(4):901-904. PubMed ID: 29693336
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
24. Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.
Hagiwara S; Sasaki E; Hasegawa Y; Suzuki H; Nishikawa D; Beppu S; Terada H; Sawabe M; Takahashi M; Hanai N
Cancer Med; 2021 Feb; 10(4):1335-1346. PubMed ID: 33565282
[TBL] [Abstract][Full Text] [Related]
25. Tissue expression, serum and salivary levels of IL-10 in patients with head and neck squamous cell carcinoma.
Hamzavi M; Tadbir AA; Rezvani G; Ashraf MJ; Fattahi MJ; Khademi B; Sardari Y; Jeirudi N
Asian Pac J Cancer Prev; 2013; 14(3):1681-5. PubMed ID: 23679256
[TBL] [Abstract][Full Text] [Related]
26. NFκB-p50 as a blood based protein marker for early diagnosis and prognosis of head and neck squamous cell carcinoma.
Gupta A; Kumar R; Sahu V; Agnihotri V; Singh AP; Bhasker S; Dey S
Biochem Biophys Res Commun; 2015 Nov; 467(2):248-53. PubMed ID: 26435503
[TBL] [Abstract][Full Text] [Related]
27. Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: Systematic review and meta-analysis.
Travassos DC; Fernandes D; Massucato EMS; Navarro CM; Bufalino A
J Oral Pathol Med; 2018 Jan; 47(1):3-10. PubMed ID: 28600896
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 predicts recurrence and survival among head and neck cancer patients.
Duffy SA; Taylor JM; Terrell JE; Islam M; Li Y; Fowler KE; Wolf GT; Teknos TN
Cancer; 2008 Aug; 113(4):750-7. PubMed ID: 18536030
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of altered blood and tissue glutathione levels in head and neck squamous cell carcinoma cases.
Khan SU; Mahjabeen I; Malik FA; Kayani MA
Asian Pac J Cancer Prev; 2014; 15(18):7603-9. PubMed ID: 25292035
[TBL] [Abstract][Full Text] [Related]
30. Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma.
Yamashita T; Shimada H; Tanaka S; Araki K; Tomifuji M; Mizokami D; Tanaka N; Kamide D; Miyagawa Y; Suzuki H; Tanaka Y; Shiotani A
Cancer Med; 2016 Mar; 5(3):415-25. PubMed ID: 26798989
[TBL] [Abstract][Full Text] [Related]
31. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
32. Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract.
Wang WL; Chang WL; Yeh YC; Lee CT; Chang CY; Lin JT; Sheu BS
Mol Carcinog; 2013 Jun; 52(6):438-45. PubMed ID: 22241750
[TBL] [Abstract][Full Text] [Related]
33. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma.
Alhamarneh O; Agada F; Madden L; Stafford N; Greenman J
Head Neck; 2011 Mar; 33(3):415-23. PubMed ID: 20645289
[TBL] [Abstract][Full Text] [Related]
34. High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer.
Rosenberg V; Pastorekova S; Zatovicova M; Vidlickova I; Jelenska L; Slezak P
Bratisl Lek Listy; 2016; 117(4):201-4. PubMed ID: 27075382
[TBL] [Abstract][Full Text] [Related]
35. Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.
Chen WC; Lai CH; Chuang HC; Lin PY; Chen MF
Head Neck; 2017 Feb; 39(2):347-355. PubMed ID: 27696591
[TBL] [Abstract][Full Text] [Related]
36. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
Byers LA; Holsinger FC; Kies MS; William WN; El-Naggar AK; Lee JJ; Hu J; Lopez A; Tran HT; Yan S; Du Z; Ang KK; Glisson BS; Raso MG; Wistuba II; Myers JN; Hong WK; Papadimitrakopoulou V; Lippman SM; Heymach JV
Mol Cancer Ther; 2010 Jun; 9(6):1755-63. PubMed ID: 20530716
[TBL] [Abstract][Full Text] [Related]
37. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
Kuropkat C; Lippert BM; Werner JA
Oncology; 2002; 63(3):280-5. PubMed ID: 12381908
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
Park MJ; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2018 Mar; 92():69-76. PubMed ID: 29428866
[TBL] [Abstract][Full Text] [Related]
39. The balance of serum IL-18/IL-37 levels is disrupted during the development of oral squamous cell carcinoma.
Ding L; Zhao X; Zhu N; Zhao M; Hu Q; Ni Y
Surg Oncol; 2020 Mar; 32():99-107. PubMed ID: 31983439
[TBL] [Abstract][Full Text] [Related]
40. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck.
Hoffmann TK; Sonkoly E; Homey B; Scheckenbach K; Gwosdz C; Bas M; Chaker A; Schirlau K; Whiteside TL
Head Neck; 2007 May; 29(5):472-8. PubMed ID: 17111427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
